Categories
Market Reports News

Bipolar Depression Epidemiology Forecast till 2030

Bipolar Disorder Manic Depression Epidemiology Forecast

DelveInsight’s ‘Bipolar Disorder Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Bipolar Disorder (Manic Depression) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bipolar Disorder, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed).

Bipolar Depression Epidemiology Segmentation in 7 Major Market from 2017 to 2030

  • Total Diagnosed Prevalence of Bipolar Depression
  • Type-specific Diagnosed Prevalence of Bipolar Depression
  • Severity-specific Diagnosed Prevalence of Bipolar Depression

Bipolar Depression Epidemiology Insights

  • The total diagnosed prevalent population of Bipolar Depression in 7MM in 2017- 1,857,545
  • The diagnosed prevalence of Bipolar Depression in 2017
  • United States – 740,715
  • France – 278,145
  • Spain – 89,599
  • Japan – 210,902
    Severity-specific diagnosed prevalence of Bipolar Depression in the US in 2017
  • 28,666- Mild cases
  • 158,735 – Moderate cases
  • 553,092 – Severe cases
    Type-specific diagnosed prevalent cases of Bipolar Depression in the US in 2017
  • Bipolar I cases – 291,134
  • Bipolar II cases – 449,581

Request for sample pages
Table of contents

1. Key Insights

2. Executive Summary of Bipolar Disorder (Manic Depression)

3. Bipolar Disorder (Manic Depression): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Bipolar Disorder (Manic Depression) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Bipolar Disorder (Manic Depression) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Bipolar Disorder (Manic Depression) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Bipolar Disorder (Manic Depression) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Bipolar Disorder (Manic Depression) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Bipolar Disorder (Manic Depression) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Bipolar Disorder (Manic Depression) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Bipolar Disorder (Manic Depression) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Bipolar Disorder (Manic Depression) Treatment and Management

6.2. Bipolar Disorder (Manic Depression) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

By sthakur

DelveInsight is a business consulting firm with deep industry expertise in life science vertical with core focus on pharma and biotech industries. We consistently help our clients in taking sound decisions facilitating better business performances and achieving incredible growth.
Since its inception, DelveInsight has played a pioneering role in providing state of the art services to its clients and prompting informed speculations of the probable prevailing market trends.